Valrubicin

Summary

Valrubicin (CHEMBL1096885) is an approved small molecule (ATC L01DB09); indicated across 5 conditions including neoplasm and carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01DB09
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 723.6 Da · C34H36F3NO13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1096885
Name	Valrubicin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	454216
ATC	L01DB09
Molecular formula	C34H36F3NO13
Molecular weight	723.6
InChIKey	ZOCKGBMQLCSHFP-KQRAQHLDSA-N

SMILES: CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O

IUPAC name: [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate

Also known as: AD 32, AD-32, NSC-246131, Valrubicin, Valrubicina, Valrubicine, Valstar, Valstar preservative free, VALRUBICIN, SID144205810, valrubicin

Patent coverage: 10,133 distinct patent families (41,463 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 41,121 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, ATP-binding cassette sub-family C member 2, ATP-binding cassette sub-family C member 3, Bile salt export pump.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
carcinoma	4	MONDO:0004993	EFO:0000313
urothelial carcinoma	3	MONDO:0040679	EFO:0008528
in situ carcinoma	3	MONDO:0004647	MONDO:0004647

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003725	PHASE3	UNKNOWN	Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
NCT01316874	PHASE2/PHASE3	COMPLETED	Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
NCT00003129	PHASE2	COMPLETED	Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
NCT00003759	PHASE2	COMPLETED	AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
NCT01606345	PHASE1	COMPLETED	Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).